addiction | CARLAT PUBLISHING

RESEARCH UPDATE

Is Ibogaine Safe for Opioid Detox?

January 30, 2023

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

Ibogaine is being promoted as a natural and safe way to detox from
opioids. Researchers here find that ibogaine is not quite as benign as some might believe.

RESEARCH UPDATE

Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Trial

January 30, 2023

Olaniyi Olayinka, MD.

Olaniyi Olayinka, MD. Dr. Olayinka has no financial relationships with companies related to this material.

Everyone knows that drinking alcohol can impair driving ability. Researchers here demonstrate that driving under the influence of cannabis can be risky as well.

RESEARCH UPDATE

Thiamine Supplementation in Patients With Alcohol Use Disorder

January 30, 2023

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

We review an article that examines rates of thiamine supplementation for those with alcohol use disorder in the real world. Researchers wondered, how often is thiamine supplemented properly? The answer they found: not that often.

EXPERT Q&A

Buprenorphine and Dental Issues

January 30, 2023

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP.

Deputy editor for The Carlat Addiction Treatment Report. Professor, Keck Graduate Institute School of Pharmacy. Claremont, CA.

Dr. Puzantian has no financial relationships with companies related to this material.

Buprenorphine is a first line treatment for opioid use disorder and has saved countless lives, but new warnings about associations between certain buprenorphine formulations and dental problems have people worried. Here, Dr. Puzantian reviews the data and shows us how to apply this new information to clinical care.

EXPERT Q&A

Managing Alcohol Withdrawal in the Emergency Department

January 30, 2023

Brian Fuehrlein, MD, PhD

Brian Fuehrlein, MD, PhD.

Addiction psychiatrist. Associate professor of psychiatry, Yale University. Director of the psychiatric emergency department at VA Connecticut. West Haven, CT.

Dr. Fuehrlein has no financial relationships with companies related to this material.

Alcohol withdrawal is among the most commonly encountered scenarios managed by psychiatrists in the ED. Here, Dr. Fuehrlein discusses the natural history of alcohol withdrawal, how best to assess withdrawal risk, and choose between treatment options.

CLINICAL UPDATE

What to Know About Injectable Buprenorphine (Sublocade)

January 30, 2023

Audrey Abelleira, PharmD, BCPP

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, Pain Management and Opioid Safety Program Coordinator, VA Connecticut Healthcare System. Clinical instructor, Yale School of Medicine. New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

Various formulations of buprenorphine abound, and a new long-acting injectable form (Sublocade) is one of the latest arrivals. But does it actually work? Here, we review the pharmacology behind it, go over efficacy data, and provide guidance on how to decide when to consider long-acting injectable buprenorphine for your patients.

Supervised Drug Consumption Sites

November 14, 2022

Noah Capurso, MD, MHS and Christopher Clayton, MD, EdM

Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

RESEARCH UPDATE

Office-Based Opioid Treatment

October 31, 2022

Joshua Blum MD

Joshua Blum, MD. Dr. Blum, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Some providers may be reluctant to treat patients with opioid use disorders with MOUD, especially in a busy primary care setting, fearing that these patients are “too complex.” In this observational study, investigators found that patients on MOUD are not all that different from everyone else.

CLINICAL UPDATE

Trauma and Addiction

October 31, 2022

Will Rutland MD, JD, MPH

Will Rutland, MD, JD, MPH. Assistant Professor and Psychiatry Clerkship Director, UAB Heersink, School of Medicine, Montgomery Regional Campus. Montgomery, AL.

Dr. Rutland, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Here, we describe treatment approaches for patients with comorbid addiction and PTSD.

RESEARCH UPDATE

Phenobarbital vs Lorazepam in Alcohol Withdrawal

October 31, 2022

Clayton Barnes, MD

Barnes Clayton, MD. Dr. Barnes, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Barbiturates and benzodiazepines are both commonly used for alcohol detoxification. But how do they compare to one another? Here, researchers found some intriguing benefits of phenobarbital.